that’s right and the new cohort is expected to perform better as they will be limited to the 60 mg well tolerated dose so the medians should all rise is what James was saying.
efison report may not adjust the evaluation up until the data of the second cohort is but they first data set shows they will be and the second should out perform the first set
great to see the SP is still sitting 35% up from a week ago today when we entered a trading halt and we will see as time moves on what the new base line is
we have December 10 around the corner !
KZA Price at posting:
59.5¢ Sentiment: Buy Disclosure: Held
